BACKGROUND: In a HCV genotype 3a-infected patient, viremia with a different genotype (1b) was detected after 16 weeks of ineffective therapy. Serological typing revealed that this genotype had already been present prior to therapy. OBJECTIVES: To investigate the epidemiology of multiple HCV infections and the therapeutical consequences for patients superinfected with a new HCV strain. METHODS: Sera of 600 patients were screened for infection with multiple genotypes by using sequencing and a serological assay in parallel. RESULTS: Infection with two different HCV types was detected in 13 patients. The prevailing strain was genotyped by sequencing. From two of these patients additional sera were available which had been drawn up to 24 and 28 months prior to the current sample, respectively. Those early samples showed viremia with a HCV subtype that could not be detected by PCR afterwards. Only antibodies to the initial strain were detectable in the later samples. CONCLUSION: In patients serially infected by different HCV strains, one strain will prevail as the viremic virus. Under antiviral therapy, the displaced strain may become viremic again and may influence the outcome of therapy. Detection of inferior strains by serological assays before antiviral therapy may be important for choosing the adequate regimen.
BACKGROUND: In a HCV genotype 3a-infected patient, viremia with a different genotype (1b) was detected after 16 weeks of ineffective therapy. Serological typing revealed that this genotype had already been present prior to therapy. OBJECTIVES: To investigate the epidemiology of multiple HCV infections and the therapeutical consequences for patients superinfected with a new HCV strain. METHODS: Sera of 600 patients were screened for infection with multiple genotypes by using sequencing and a serological assay in parallel. RESULTS:Infection with two different HCV types was detected in 13 patients. The prevailing strain was genotyped by sequencing. From two of these patients additional sera were available which had been drawn up to 24 and 28 months prior to the current sample, respectively. Those early samples showed viremia with a HCV subtype that could not be detected by PCR afterwards. Only antibodies to the initial strain were detectable in the later samples. CONCLUSION: In patients serially infected by different HCV strains, one strain will prevail as the viremic virus. Under antiviral therapy, the displaced strain may become viremic again and may influence the outcome of therapy. Detection of inferior strains by serological assays before antiviral therapy may be important for choosing the adequate regimen.
Authors: Evan B Cunningham; Tanya L Applegate; Andrew R Lloyd; Gregory J Dore; Jason Grebely Journal: Nat Rev Gastroenterol Hepatol Date: 2015-03-17 Impact factor: 46.802
Authors: Jayna Raghwani; Xiomara V Thomas; Sylvie M Koekkoek; Janke Schinkel; Richard Molenkamp; Thijs J van de Laar; Yutaka Takebe; Yasuhito Tanaka; Masashi Mizokami; Andrew Rambaut; Oliver G Pybus Journal: J Virol Date: 2011-11-23 Impact factor: 5.103
Authors: Jennifer A Smith; Judith H Aberle; Vicki M Fleming; Peter Ferenci; Emma C Thomson; Peter Karayiannis; Angela R McLean; Heidemarie Holzmann; Paul Klenerman Journal: J Infect Dis Date: 2010-11-10 Impact factor: 5.226
Authors: Paulo Telles Dias; Judith A Hahn; Eric Delwart; Brian Edlin; Jeff Martin; Paula Lum; Jennifer Evans; Alex Kral; Steve Deeks; Michael P Busch; Kimberly Page Journal: BMC Infect Dis Date: 2011-08-02 Impact factor: 3.090
Authors: Anna L McNaughton; Iain Dugald Cameron; Elizabeth B Wignall-Fleming; Roman Biek; John McLauchlan; Rory N Gunson; Kate Templeton; Harriet Mei-Lin Tan; E Carol McWilliam Leitch Journal: J Virol Date: 2015-08-26 Impact factor: 5.103